source · application/json
source_8d2025a390f14a8a
sha256 dae43405a2641ad40aa1afcf0b82874485aa83f6f4844abdd134dfa9cab4baf8
by researka:v2 · 2026-06-20 09:34:04.154348+04:00
{"content_hash": null, "edges": [{"from": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "to": "claim_1", "type": "contains_claim"}, {"from": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "to": "claim_2", "type": "contains_claim"}, {"from": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "to": "claim_3", "type": "contains_claim"}, {"from": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "to": "claim_4", "type": "contains_claim"}, {"from": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "to": "claim_5", "type": "contains_claim"}, {"from": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "to": "claim_6", "type": "contains_claim"}, {"from": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "to": "claim_7", "type": "contains_claim"}, {"from": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "to": "claim_8", "type": "contains_claim"}, {"from": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "to": "claim_9", "type": "contains_claim"}, {"from": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "to": "claim_10", "type": "contains_claim"}, {"from": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "to": "claim_11", "type": "contains_claim"}, {"from": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "to": "claim_12", "type": "contains_claim"}], "nodes": [{"id": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "title": "SGLT2 inhibitors: evidence map — 24 findings across 24 sources", "type": "publication"}, {"id": "claim_1", "text": "This evidence map surveys 24 independent SGLT2 inhibitors sources drawn from the Tier-2 corpus and classified as direct findings. They vary across population, comparator, and/or endpoint and are catalogued by source in the Findings Map rather than pooled into one estimate — cross-population aggregation is not claimed. Each row records its own population, comparator, endpoint, and effect, so the spread of the literature and any tensions between findings remain explicit.", "type": "claim"}, {"id": "claim_2", "text": "| individuals with CKD, with or without… | — | SGLT2 inhibitors reduce the risk of kidney failure and other major kidney outcomes by 30%–… | 2024 doi:10.34067/kid.0000000000000425 |", "type": "claim"}, {"id": "claim_3", "text": "| U.S. SGLT-2 inhibitor prescriptions | 2016 baseline | Another study reported a 114.6% increase in prescription rates between 2016 and 2021 | 2023 doi:10.1136/bmjdrc-2023-003666 |", "type": "claim"}, {"id": "claim_4", "text": "| type 2 diabetic patients | — | canagliflozin (100 mg/die) increased VLHDL by 10.9% after 12 weeks | 2021 doi:10.3390/metabo11020087 |", "type": "claim"}, {"id": "claim_5", "text": "| non-diabetic mice with transverse aort… | vehicle | Empagliflozin also increased exercise endurance by 36% in mice with transverse aortic cons… | 2021 doi:10.1161/jaha.120.018298 |", "type": "claim"}, {"id": "claim_6", "text": "| >40 000 patients across five large-sca… | — | SGLT2 inhibitors decreased the risk of serious heart failure events by 25-40% | 2020 doi:10.1002/ejhf.1732 |", "type": "claim"}, {"id": "claim_7", "text": "| patients with type 2 diabetes | — | lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk o… | 2020 doi:10.3390/diseases8020014 |", "type": "claim"}, {"id": "claim_8", "text": "| patients with renal impairment | subjects with normal renal f… | Mild, moderate, and severe renal impairment were associated with a ≤70% increase in ertugl… | 2020 doi:10.1007/s40262-020-00875-1 |", "type": "claim"}, {"id": "claim_9", "text": "| patients with type 2 diabetes mellitus | insulin or GLP-1RA | SGLT-2i showed a greater decrease of PWV (10.1%) than insulin or GLP-1RA. | 2020 doi:10.1161/jaha.119.015716 |", "type": "claim"}, {"id": "claim_10", "text": "| diabetic db/db mice | vehicle-treated db/db mice | cardiac ATP production rates increased by 31% compared with db/db vehicle-treated mice | 2018 doi:10.1016/j.jacbts.2018.07.006 |", "type": "claim"}, {"id": "claim_11", "text": "| subgroup of patients with baseline uri… | glimepiride | In patients with UACR ≥30 mg/g, canagliflozin 100 mg decreased UACR by 31.7% (95% CI, 8.6%… | 2016 doi:10.1681/asn.2016030278 |", "type": "claim"}, {"id": "claim_12", "text": "| patients with T2DM and increased cardi… | earlier baseline period | relative risk reductions in major adverse cardiac events (14%) | 2016 doi:10.2174/1573399812666160613113556 |", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": "10.4093/dmj.2025.0220", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/40367988/", "year": 2025}, {"comparator": "not extracted", "directness": "primary", "doi": "10.34067/kid.0000000000000425", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "SGLT2 Inhibitors and Kidney Protection: Mechanisms Beyond Tubuloglomerular Feedback", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/38523127/", "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fphar.2024.1364110", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/38860168/", "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1136/bmjdrc-2023-003666", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/37797963/", "year": 2023}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1093/ckj/sfad082", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/37529652/", "year": 2023}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/ijms23073651", "effect": "not extracted", "endpoint": "not extracted", "id": "source_6", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/35409011/", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1111/acel.13653", "effect": "not extracted", "endpoint": "not extracted", "id": "source_7", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Neuroprotective effects of Canagliflozin: Lessons from aged genetically diverse UM‐HET3 mice", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/35707855/", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1038/s41591-022-02120-7", "effect": "not extracted", "endpoint": "not extracted", "id": "source_8", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/36477733/", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fcvm.2021.747620", "effect": "not extracted", "endpoint": "not extracted", "id": "source_9", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/34746262/", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/metabo11020087", "effect": "not extracted", "endpoint": "not extracted", "id": "source_10", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "The Effects of SGLT2 Inhibitors on Lipid Metabolism", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/33535652/", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3389/fphar.2021.664181", "effect": "not extracted", "endpoint": "not extracted", "id": "source_11", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/33995090/", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/jaha.120.018298", "effect": "not extracted", "endpoint": "not extracted", "id": "source_12", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Direct Cardiac Actions of the Sodium Glucose Co‐Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure‐Overload Heart Failure", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/33719499/", "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1002/ejhf.1732", "effect": "not extracted", "endpoint": "not extracted", "id": "source_13", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/32037659/", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.3390/diseases8020014", "effect": "not extracted", "endpoint": "not extracted", "id": "source_14", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/32403420/", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1172/jci.insight.140019", "effect": "not extracted", "endpoint": "not extracted", "id": "source_15", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Canagliflozin extends life span in genetically heterogeneous male but not female mice", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/32990681/", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1007/s40262-020-00875-1", "effect": "not extracted", "endpoint": "not extracted", "id": "source_16", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/32337660/", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/jaha.119.015716", "effect": "not extracted", "endpoint": "not extracted", "id": "source_17", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/32326806/", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1002/ejhf.1978", "effect": "not extracted", "endpoint": "not extracted", "id": "source_18", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "type": "source", "url": null, "year": 2020}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1177/2047487318755531", "effect": "not extracted", "endpoint": "not extracted", "id": "source_19", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/29372664/", "year": 2018}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1016/j.jacbts.2018.07.006", "effect": "not extracted", "endpoint": "not extracted", "id": "source_20", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Empagliflozin Increases Cardiac Energy Production in Diabetes", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/30456329/", "year": 2018}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1186/s12933-018-0745-5", "effect": "not extracted", "endpoint": "not extracted", "id": "source_21", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/29991346/", "year": 2018}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/circulationaha.116.021887", "effect": "not extracted", "endpoint": "not extracted", "id": "source_22", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/27470878/", "year": 2016}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1681/asn.2016030278", "effect": "not extracted", "endpoint": "not extracted", "id": "source_23", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/27539604/", "year": 2016}, {"comparator": "not extracted", "directness": "primary", "doi": "10.2174/1573399812666160613113556", "effect": "not extracted", "endpoint": "not extracted", "id": "source_24", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials", "type": "source", "url": "https://pubmed.ncbi.nlm.nih.gov/27296042/", "year": 2016}], "publication_id": "6a95d805-9bed-4d50-9674-754d8b52c1ea", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 24, "included": 24, "included_or_retained": 24, "screened": 24, "wording": "24 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "6a95d805-9bed-4d50-9674-754d8b52c1ea",
"researka_submission_id": "7abad27c-ced9-4337-8404-5455a10591da",
"sidecar_name": "claim_graph.json",
"sidecar_url": "https://api.researka.org/publications/6a95d805-9bed-4d50-9674-754d8b52c1ea/sidecars/claim_graph.json"
}